Pivotal BioSciences

Pivotal BioSciences is a clinical-stage biotechnology company focused on developing innovative immunotherapies for solid tumors. The company's core technology is based on a proprietary platform that creates fusion proteins designed to target the necrotic core of tumors. By linking potent cytokines to a DNA-binding monoclonal antibody fragment, Pivotal BioSciences enables the localized delivery of immune stimulants directly into the tumor microenvironment. This targeted approach is intended to maximize anti-tumor activity while significantly reducing the systemic toxicity often associated with cytokine treatments. The company's lead candidate, PVT-001, leverages this 'Universal Cytokine' technology to treat advanced malignancies. Founded on research from the University of Southern California, the company continues to advance its pipeline through clinical and translational studies.